The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So given one of the links above states that the Accustem listing is likely for Q3....
As I recall, TILS gave them £1m working capital in the £3m spin off.
Given that the listing period seems to be likely to be Q3 (still tbc by the company btw), which I believe is quite a bit longer than TILS originally envisaged, I wonder whether the £1m will be enough, and if not, how will they raise any additional requirement?
I would think that one option would be to issue a promissory note pledging x value of shares (obviously to include interest payments) in the new company - but anyone taking on that risk is going to want a large chunk of the action, which may well effectively devalue our piece of the pie. (It may, of course, be funded by TILS themselves but they won't be giving it away either!)
Maybe the £1m will be enough but if not I hope whatever options there are aren't too expensive!
If (when) they get a product to market we'll see a fair price. I'll be holding until then.
I suddenly had a thought, TradePhoenix, that given your comment above, you probably don't realise that the preparation of the 40 page research note is indirectly paid for in it's entirety by TILS. It'd therefore be rude of them to place a low value on the company, even if they thought so.
So much as I'd love $7.50 (or more!!), don't hold your breath...
I meant fake news in a slightly humorous way but the fact remains that as far as I can see the company's own press release and the RNS didn't state a timeframe, so it's not unreasonable to question the source.
And anyway, I bet we don't see $7.50 either. I'd love it if we did!!!
Denny, highly doubt the company that created a 40 page research note and quoted a price of $7.50 is posting fake news.
.... see my post immediately above but also the press release does not mention third quarter so I don't know where the website might have got that info. Maybe it's fake news.
I guess the bit of the webpage you have quoted is superseded by yesterday's RNS.
There won't be an LSE listing date. The RNS states they have decided to list only on NASDAQ.
Although the article linked to above states 3rd quarter I don't recall seeing any dates in the RNS. If true it is a big disappointment but not the end of the world really. These things do take time.
Accustem paragraph on Tiziana website under about us section
Tiziana Life Sciences completed the demerger of StemPrinter from the company on October 30th, 2020. It is now expected that the Accustem Shares will have a standard listing on the Official List and be admitted to trading on the London Stock Exchange. The Tiziana Shares will retain their LSE listing but a process is underway to seek admission to the standard segment of the Official List and trading on the London Stock Exchange. It is expected that Accustem Admission will occur during Q1, 2021.
The above paragraph is taken from the Tiziana website with the expectation of trading Accustem on the LSE so if this has changed then IMO I would expect that there would have been an RNS to confirm a significant change of direction. So the recent RNS of their intent to trade on the Nasdaq I would take as additional significant news and unless we are told any different then the only problem at the moment is the delay in the shares allocation and the LSE listing date.
Well it’s a classic de-ramp tactic to bash the BOD.
I don’t know any share that has had a significant patent application granted where the share price hasn’t increased significantly. Patents are a defining contribution to share value. In fact I feel so strongly now that this share is being manipulated I may even take it up with the FCA.
Regards,
I’m a holder and whilst I’m in awe of the science and the potential benefits, I’m frustrated and underwhelmed by the business acumen. Not trying to get anyone to sell, just not satisfied with the BODs performance and communication.
You chaps are really pushing the boat out now aren’t you to bash TILS. This is totally outrageous now, and no mention anywhere about the amazing implications of that new patent (years in the making) which will quickly being in revenue.
If you think you are going to get any more of us LTH to sell our shares then you can all
GO JUMP IN A LAKE!!!
WE ARE NOT SELLING SO GET LOST!!!
Unbelievable!!!
I can see why this would get shorted. Whilst they may be s*** hot on the science side of things, as a business and therefore investment the BOD are clueless.
3rd quarter? This is new and totally outside of reasonable expectation for this deal. I have lost all confidence in this board of directors.
Incidentally, I emailed them yesterday to ask for clarification over the dual vs Nasdaq only listing and pointing out the confusion they have caused. No reply at this point.
Total shambles.
And there is me last October thinking I would be selling up at 5 quid a share in July. Doh !!!
"The listing is expected to transpire during the third quarter and will provide additional liquidity and price transparency to investors."
So we are expecting the listing between July-September? Where did it get this information? If this is the case, I lost word for the demerge and listing process, what a mess, full of delay and confusion!
Recent article on Accustem:
https://scr.zacks.com/news/news-details/2021/TLSA-Accustem-Converging-on-NASDAQ/default.aspx